• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Global Biosciences Co. Selects ValGenesis VLMS

    Eisai Appoints Chief Clinical Officer of Oncology Biz

    Nexelis Acquires GSK Vax Lab in Marburg

    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal

    NovaQuest Private Equity Acquires CoreRx
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules

    Cognate BioServices Announces Major Expansion

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I

    JS Bio and Etta Biotech Advancing Partnership

    Intravacc Completes Project for Provention Bio’s Vax Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Alcami

    Syngene

    Reed-Lane

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Cytovance Biologics

    Reed-Lane

    Syngene

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Flamma Arrives in the U.S.

    Italian CDMO sets down roots in the U.S. market with purchase of Teva facility.

    Flamma Arrives in the U.S.
    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Regis Custom Pharma
    • FLAMMA
    Tim Wright, Editor, Contract Pharma10.15.19
    Flamma SpA, a contract development and manufacturing organization (CDMO) that develops, manufactures, and commercializes small molecule active pharmaceutical ingredients (APIs) for the pharmaceutical industry, acquired Teva’s Chemical Synthesis Center in Malvern, PA in the Philadelphia area, earlier this year in July.

    Dubbed “Flamma-delphia,” the 40,000 square foot facility, with lab and manufacturing capabilities, possesses a cGMP pilot plant with hydrogenation capabilities as well as wet-milling, six standard cGMP kilo lab suites, one cGMP HPAPI kilo lab suite with isolators that have been classified 3b (Roche) or band 4 (Safebridge), 22 fume hoods, an analytical development lab, as well as a QC lab, and additional space for future expansion for any necessary analytical, chemistry, and/or  warehouse needs. Also, the site previously handled controlled drug substances (Schedule II to IV) and Flamma says it looks forward to reactivating the necessary licenses.

    This site will initially be dedicated to the development and production of APIs ranging from preclinical/clinical (Phases 1 to 3) and up to commercial phase (after future FDA inspection) with the scale being dependent on the forecasted quantities. Flamma plans to grow the site to 60 employees by 2023.

    This acquisition comes on the heels of the addition of a cGMP workshop at Flamma Honkai and the recent receipt of a cGMP drug manufacturing license from the Chinese FDA. Flamma’s Italian sites also recently added a new cGMP kilo lab as well as a high containment lab to handle genotoxic materials. Flamma intends to invest approximately $10 million to expand its R&D capabilities with the addition of a new R&D building at its Chignolo d’Isola headquarters soon.

    Recently, Contract Pharma had the chance to talk with Ken Drew, Flamma’s senior director of North America sales and business development about the facility purchase and other company news, as well as larger industry trends.

    Contract Pharma (CP): What was the strategy behind the acquisition of Teva’s facility?

    Ken Drew (KD):
    Flamma had been looking to have a location in the U.S. for the past several years. While many in the CDMO industry grew by consolidation, Flamma decided not to overreact and continue to look for a facility that was a good fit. The Teva facility allows Flamma to quickly move to a position where we can offer cGMP pilot plant scale projects in the U.S. while maintaining our fully integrated system for customers looking to have a secure supply chain. Having sites in Italy and China and now the U.S., Flamma can provide a variety of options for our customer base. 

    CP: What capabilities does the new facility provide and how will it foster future growth for Flamma?

    KD:
    Flamma will continue to be true to itself and do what we do best. The consolidation of CDMOs to include drug product along with drug substance is something that we don’t feel is necessary to provide quality service. Flamma can now provide those companies that want to remain close to home in the U.S., a place to take early stage development projects. The projects with quantities from 1-20 kg seem to be a perfect fit. These can be APIs, RSMs, NCEs, or advanced intermediates.

    It also allow us to continue to grow our niche generic portfolio that takes advantage of our skill set with high value amino acid derivatives. We also have a new R&D team that is ready to be part of the already fantastic R&D team.


    “Flamma-delphia” on the inside. (Credit: Flamma)

    CP: In which area is Flamma observing the greatest growth from clients, and in which geographies are these firms based?

    KD:
    It is difficult to determine where the greatest growth is coming from since our customer base combines new customers along with old customers who consider Flamma a preferred supplier or their “go to” CDMO. We are seeing customers from the U.S., Europe, and Asia come to us with projects that seem to fit well with our small molecule toolbox.

    CP: What do you predict for the future of small molecule development? Combination therapies? More complex molecules?

    KD: It is clear that small molecules are becoming more complex. The days of a simple five step synthesis are over. We are seeing molecules that require very advanced intermediates that often come from numerous synthetic steps. We like to back integrate projects so, if we can, we will look to Flamma Honkai, our facility in Dalian, China, to see if we can bring value by making the materials in house and simplifying the supply chain.

    By bringing this value forward, we gain a greater control over the supply chain for the customer who, in turn, can either have Flamma continue to make the material for them or use our costing and scheme to have it made elsewhere. This frees up our internal resources to work on more advanced materials for customers.

    The move, when appropriate, toward flow chemistry is still very interesting and is something Flamma is undertaking. The issue is that not every synthetic scheme lends itself to flow chemistry so batch chemistry will continue to be part of the toolbox any CDMO uses.

    CP: What are some of the crucial issues impacting pharma manufacturing and supply and CDMOs in particular?

    KD:
    One of the most critical issues that many people are overlooking is the potential shortage of basic chemicals. The environmental changes in China have caused many companies that made simple basic materials and solvents to close. This has caused the cost of many so-called common materials and solvents to increase dramatically in price and become in short supply.

    Flamma has been very proactive in either stocking more materials and solvents where we see potential shortages as well as sourcing from multiple suppliers to decrease the risk of shortages. Customers will not tolerate, and should not tolerate, the excuse that our supplier was late or short of material. It’s our job to make sure we do our job as best as we can.

    CP: How are partnerships in external development and manufacturing evolving, and what does the future hold?

    KD:
    The consolidation of the CDMO industry has been discussed ad nauseam. That said, it has also provided innovators a look at how they outsource their small molecules. For Flamma, consolidation has been great since our customers value the family run, family owned business model that we have.

    Customers are looking for long term relationships and partnerships. Becoming part of a preferred supplier list or considered the CDMO that solves problems as opposed to making them is what Flamma strives to be. Full transparency not only in the way we handle projects but in the way we provide quotes allows a customer to see what exactly is going on. Raw material table breakdowns allow customers to compare apples to apples.

    By giving a fair price along with realistic time lines and then delivering on time and in spec is what we do. Those experienced sourcing managers realize that the size of the CDMO and the project’s costs need to be evaluated against the track record and reputation of the CDMO. 

    CP: What demand are you seeing for the outsourcing of small molecules? Why strengthen in this space?

    KD:
    Small molecules are not going away. They are being used in many different facets. They are being used in new drug delivery systems, ADCs, etc. While they are becoming more complex, the innovators need to understand the CDMO marketplace and realize who has the ability to handle their molecules. Flamma’s experience dates back to 1950. That experience translates to the ability to handle sophisticated molecules such as ones that are high value chiral molecules like amino acids.

    The need is there, and having a fully integrated CDMO that can go from small kilos to metric tons, from the U.S. to Italy and/or China to Italy is needed.

    CP: In addition to the newly acquired facility, what are some other business highlights from the past 12 months?

    KD:
    Flamma’s Dalian, China site, Flamma Honkai, had its initial Chinese FDA inspection and we also acquired additional land for our expansion plans there. These important milestones allow us to build upon our successes as Flamma continues to service our customers.

    Flamma also completed construction of a cGMP kilo lab at our Chignolo D’Isola headquarters in Italy. Customers looking for a CDMO with a long-term vision that is transparent have embraced Flamma’s vision.

    CP: What is next for Flamma?

    KD:
    Flamma has also purchased parcels of land at both Italian sites to allow for future expansion such as the new R&D building at Chignolo D’Isola headquarters scheduled to start construction later this year. This $10 million addition will provide a new R&D building that will quadruple our R&D space. This will allow Flamma to continue to grow our staff of researchers that serve the pharma industry, the demands of our current customers as well as future customers.

    As mentioned previously, Flamma Honkai will look to expand on the land acquired there with the addition of another workshop as we smartly expand to meet the demands made by customers.

    CP: What else can you tell us about Flamma?

    KD:
    Flamma is a family owned, family run company since its beginnings and because of this, Flamma’s culture is very much like a family. Each and every employee regardless of their location is part of the Flamma family and culture. We think that the combination of our family spirit, which also embraces harmony and respect, along with our competent and strong scientific background, will continue to allow us to successfully grow as a leader in the small molecule CDMO arena.

    Flamma always tries to build long-term partnerships that are an extension of the customer’s team. By having the same team follow a project from the start gives customers a certain piece of mind that Flamma carries an internal knowledge of the project. This helps to solve issues quickly. We are not a pair of hands but the Thinking CDMO. We help solve problems by working simultaneously together. 

    Kenneth N. Drew, Ph.D., is the Sr. Director of North America Sales and Business Development for Flamma. He joined Flamma in January 2010 as the first employee of Flamma USA. Before joining Flamma, he worked for Cambrex in a similar role. As a Ph.D. chemist, he worked in the lab for 20 years at places like Biogen before moving into the business side of the pharma industry. In these lab positions, he helped to develop a variety of drugs for colon cancer, congestive heart failure, and many others. This knowledge of what it takes to develop a drug has served him well when dealing with customers looking to place small molecule projects for CMC.
    Related Searches
    • expansion
    • facility
    • roche
    • kilo lab
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    FLAMMA FLAMMA
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
    How to Survive and Thrive During CDMO Climate Change How to Survive and Thrive During CDMO Climate Change
    Contract Pharma’s 20th Anniversary Retrospective Contract Pharma’s 20th Anniversary Retrospective
    Handling & Assessing HPAPIs Handling & Assessing HPAPIs
    Changing the Face of CDMOs Changing the Face of CDMOs
    Drug Substances: Scale-Up Challenges Drug Substances: Scale-Up Challenges
    API to ADC: A Journey Through High Potency API to ADC: A Journey Through High Potency
     Roche’s Tecentriq/Abraxane Combo for TNBC Approved by EU Roche’s Tecentriq/Abraxane Combo for TNBC Approved by EU

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Virtual Clinical Trials: The Future Of Dermatology Studies
    Breaking News
    • Global Biosciences Co. Selects ValGenesis VLMS
    • Eisai Appoints Chief Clinical Officer of Oncology Biz
    • Nexelis Acquires GSK Vax Lab in Marburg
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • NovaQuest Private Equity Acquires CoreRx
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Euromonitor Names Top Ten Trends for 2021
    Study Highlights Differences Between EPA's and DHA's Effect on Sleep
    BGG Obtains U.S. Patent on AstaZine Natural Astaxanthin for Heart Function During Exercise
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Researchers Successfully ‘Fine Tune’ New Thermoplastic Biomaterial
    RSIP Vision Announces Versatile Medical Image Segmentation Tool
    Vance Street Capital Adds Operating Partner
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Global Biosciences Co. Selects ValGenesis VLMS
    Eisai Appoints Chief Clinical Officer of Oncology Biz
    Nexelis Acquires GSK Vax Lab in Marburg
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Top Beauty Brands in the World—And Most Loved Fragrances
    P&G Reports Q2 Results
    A Lacquering Technique Makes Very Good Girl by Carolina Herrera Shine
    Happi

    Latest Breaking News From Happi

    Ross Introduces Double Cone Tumble Blender
    Colonial Chemical Announces New Facility
    Ashland Acquires Schülke & Mayr's Personal Care Business
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Domino grows installation and service teams
    ABG keeps pace with demand with recruitment drive
    Acucote expands FSC-certified portfolio
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    First Quality Launches Incognito by Prevail
    Essity Launches Reusable Underwear Product
    Honeywell Delivered 225 Million Masks in December
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    DJO Acquires Trilliant Surgical
    FDA Breakthrough Device Designation Granted to Spiderwort's Spinal Cord Technology
    Bioventus Appoints SVP of Operations
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login